MedTrace Logo

Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia Management

NCT04065802 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-11-15

No results posted yet for this study

Summary

Stereotactic Arrhythmia Radioablation (STAR) ablation is a safe and feasible option for cardiomyopathy patients for management of refractory ventricular tachycardia.

STAR can be performed with available cardiac imaging, prior mapping/electrogram information, and standard ECGs without a multi-electrode ECG vest.

Conditions

  • Stereotactic Radioablation for Ventricular Tachycardia

Interventions

RADIATION

Stereotactic Radioablation

External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias

Sponsors & Collaborators

  • Libin Cardiovascular Institute of Alberta

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Vikas Kuriachan, MD · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2023-12-30
Completion
2024-12-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065802 on ClinicalTrials.gov